Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Aug 8, 2019
Strong financial performance in H1 2019 Continued positive performance of all three strategic growth drivers Guidance raised on 2019 net sales and EBITDA On track to achieve Milestone 2020 ZURICH,...
-
Jun 11, 2019
Vifor Pharma and Evotec to create a jointly-owned drug discovery and development platform for innovative nephrology therapeutics Collaboration brings together Evotec’s best-in-class drug...
-
May 26, 2019
Public-private partnership is intended to safeguard Switzerland’s competitive position in pharmaceutical technologies of the future Zurich and Basel, 26 May 2019 Nanopharmaceutics promises...
-
May 21, 2019
ZURICH, 21 May 2019 – Vifor Pharma today announced that treatment of the first patient in their global phase-IIIb DIAMOND study has begun. The study will evaluate the potential of Veltassa® to...
-
May 10, 2019
Veltassa® (patiromer) enables spironolactone for blood pressure management in patients with resistant hypertension and chronic kidney disease by controlling blood potassium levels. ZURICH, 10 May...